

M27

Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

This standard covers antifungal agent selection and preparation, test procedure implementation and interpretation, and quality control requirements for susceptibility testing of yeasts that cause invasive fungal infections.

.....
A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org

Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

Barbara D. Alexander, MD, MHS
Gary W. Procop, MD, MS
Philippe Dufresne, PhD (RMCCM)
Jeff Fuller, PhD, FCCM, D(ABMM)
Mahmoud A. Ghannoum, PhD, EMBA, FIDSA
Kimberly E. Hanson, MD, MHS
Denise Holliday, MT(ASCP)
Nicole M. Holliday, BA
Laura Kovanda, PhD
Shawn R. Lockhart, PhD, D(ABMM)
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA
Audrey N. Schuetz, MD, MPH, D(ABMM)
Nathan P. Wiederhold, PharmD
Adrian M. Zelazny, PhD, D(ABMM)

Abstract

Clinical and Laboratory Standards Institute standard M27—*Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts* describes a method for testing the susceptibility to antifungal agents of yeasts that cause invasive fungal infections, including *Candida* spp. and *Cryptococcus neoformans*. Selection and preparation of antifungal agents, implementation and interpretation of test procedures, and the purpose and implementation of QC procedures are discussed. A careful examination of the responsibilities of the manufacturer and the user in QC is also presented.

Clinical and Laboratory Standards Institute (CLSI). *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts*. 4th ed. CLSI standard M27 (ISBN 1-56238-826-6 [Print]; ISBN 1-56238-827-4 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2017.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.



Copyright ©2017 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts*. 4th ed. CLSI standard M27. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

Previous Editions:

December 1992, October 1995, June 1997, August 2002, April 2008

Committee Membership

Consensus Council

**Carl D. Mottram, RRT, RPFT,
FAARC
Chairholder
Mayo Clinic
USA**

**Dennis J. Ernst, MT(ASCP),
NCPT(NCCT)
Vice-Chairholder
Center for Phlebotomy Education
USA**

J. Rex Astles, PhD, FACB, DABCC
Centers for Disease Control and
Prevention
USA

Lucia M. Berte, MA, MT(ASCP)SBB,
DLM, CQA(ASQ)CMQ/OE
Laboratories Made Better!
USA

Karen W. Dyer, MT(ASCP), DLM
Centers for Medicare & Medicaid
Services
USA

Thomas R. Fritsche, MD, PhD, FCAP,
FIDSA
Marshfield Clinic
USA

Mary Lou Gantzer, PhD, FACB
BioCore Diagnostics
USA

Loralie J. Langman, PhD, DABCC,
FACB, F-ABFT
Mayo Clinic
USA

Ross J. Molinaro, PhD, MLS(ASCP)CM,
DABCC, FACB
Siemens Healthcare Diagnostics, Inc.
USA

Joseph Passarelli
Roche Diagnostics Corporation
USA

Andrew Quintenz
Bio-Rad Laboratories, Inc.
USA

Robert Rej, PhD
New York State Department of Health –
Wadsworth Center
USA

Zivana Tezak, PhD
FDA Center for Devices and
Radiological Health
USA

Subcommittee on Antifungal Susceptibility Tests

**Barbara D. Alexander, MD, MHS
Chairholder
Duke University Medical Center
USA**

**Gary W. Procop, MD, MS
Vice-Chairholder
Cleveland Clinic
USA**

Philippe Dufresne, PhD (RMCCM)
Institut national de santé publique du
Québec
Canada

Jeff Fuller, PhD, FCCM, D(ABMM)
London Health Sciences Centre
Canada

Staff

Clinical and Laboratory Standards
Institute
USA

Marcy L. Hackenbrack, MCM,
M(ASCP)
Project Manager

Mahmoud A. Ghannoum, PhD, EMBA,
FIDSA
Case Western Reserve University
USA

Kimberly E. Hanson, MD, MHS
University of Utah and ARUP
Laboratories
USA

Denise Holliday, MT(ASCP)
BD Diagnostic Systems
USA

Nicole M. Holliday, BA
Thermo Fisher Scientific
USA

Luis Ostrosky-Zeichner, MD, FACP,
FIDSA, FSHEA
Memorial Hermann Healthcare System
USA

Audrey N. Schuetz, MD, MPH,
D(ABMM)
Mayo Clinic
USA

Nathan P. Wiederhold, PharmD
University of Texas Health Science
Center at San Antonio
USA

Adrian M. Zelazny, PhD, D(ABMM)
USA

Megan L. Tertel, MA, ELS
Editorial Manager

Catherine E.M. Jenkins
Editor

Kristy L. Leirer, MS
Editor

Laura Martin
Editor

Acknowledgment for the Expert Panel on Microbiology

CLSI, the Consensus Council, and the Subcommittee on Antifungal Susceptibility Tests gratefully acknowledge the Expert Panel on Microbiology for serving as technical advisors and subject matter experts during the development of this standard.

Expert Panel on Microbiology

**Richard B. Thomson, Jr., PhD,
D(ABMM), FAAM
Chairholder
Evanston Hospital, NorthShore
University HealthSystem
USA**

**Mary Jane Ferraro, PhD, MPH
Vice-Chairholder
Massachusetts General Hospital
USA**

Lynette Y. Berkeley, PhD, MT(ASCP)
FDA Center for Drug Evaluation and
Research
USA

Carey-Ann Burnham, PhD, D(ABMM)
Washington University School of
Medicine
USA

German Esparza, BSc
Proasecal LTD
Colombia

Mark G. Papich, DVM, MS
College of Veterinary Medicine,
North Carolina State University
USA

Jean B. Patel, PhD, D(ABMM)
Centers for Disease Control and
Prevention
USA

David H. Pincus, MS, RM/SM(NRCM),
SM(ASCP)
bioMérieux, Inc.
USA

Audrey N. Schuetz, MD, MPH,
D(ABMM)
Mayo Clinic
USA

Ribhi M. Shawar, PhD, D(ABMM)
FDA Center for Devices and
Radiological Health
USA

Barbara L. Zimmer, PhD
Beckman Coulter - West Sacramento
USA

Acknowledgment

CLSI, the Consensus Council, and the Subcommittee on Antifungal Susceptibility Tests gratefully acknowledge the following volunteers for their important contributions to the development of this standard:

Laura Kovanda, PhD
Astellas Pharma
USA

Shawn R. Lockart, PhD, D(ABMM)
Centers for Disease Control and
Prevention
USA

Acknowledgment

CLSI, the Consensus Council, and the Subcommittee on Antifungal Susceptibility Tests gratefully acknowledge the following former subcommittee members for their review of this standard during development:

Sharon K. Cullen, BS, PMP, RAC
Beckman Coulter - West Sacramento
USA

David S. Perlin, PhD
New Jersey Medical School-UMDNJ
USA

Nancy L. Wengenack, PhD, D(ABMM)
Mayo Clinic
USA

Shawn R. Lockhart, PhD, D(ABMM)
Centers for Disease Control and
Prevention
USA

Dee Shortridge, PhD
JMI Laboratories
USA

Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
Chapter 1: Introduction.....	1
1.1 Scope.....	1
1.2 Background.....	1
1.3 Standard Precautions.....	2
1.4 Terminology.....	2
Chapter 2: Preparing for Antifungal Susceptibility Testing.....	5
2.1 Indications for Performing Antifungal Susceptibility Tests.....	5
2.2 Selecting Antifungal Agents for Routine Testing and Reporting.....	6
Chapter 3: Antifungal Broth Dilution Susceptibility Testing Process for Yeasts.....	7
3.1 Preparing Antifungal Agents.....	9
3.2 Testing Procedures.....	11
3.3 Reading Minimal Inhibitory Concentration Results.....	15
3.4 Interpreting Results.....	17
Chapter 4: Quality System Essential: Process Management – Quality Control.....	19
4.1 Quality Control Purpose.....	19
4.2 Quality Control Responsibilities.....	19
4.3 Selecting Reference Strains.....	20
4.4 Storing Reference Strains.....	20
4.5 Controlling Media Batches and Plasticware Lots.....	22
4.6 Quality Control Frequency.....	22
4.7 Other Quality Control Procedures.....	23
Chapter 5: Conclusion.....	24
Chapter 6: Supplemental Information.....	24
References.....	25
Appendix A. Preparing Dilution Series of Water-Insoluble Antifungal Agents to Be Used in Broth Dilution Susceptibility Tests.....	27
Appendix B. Composition of Roswell Park Memorial Institute 1640 Culture Medium (With Glutamine and Phenol Red but Without Bicarbonate).....	28
Appendix C. Preparing Roswell Park Memorial Institute 1640 Culture Medium.....	29
Appendix D. Preparing Dilution Series of Water-Soluble Antifungal Agents to Be Used in Broth Dilution Susceptibility Tests.....	30
Appendix E. 0.5 McFarland Barium Sulfate Turbidity Standard.....	31
The Quality Management System Approach.....	32
Related CLSI Reference Materials.....	33

Foreword

With the increased incidence of systemic fungal infections and the growing number of available antifungal agents, laboratory guidance for selecting antifungal therapy has gained greater attention. In 1982, the CLSI Area Committee for Microbiology formed the Subcommittee on Antifungal Susceptibility Tests. In 1985, this subcommittee published its first report, in which the results of a questionnaire and a small collaborative study were presented. Based on these findings, the subcommittee concluded that it would be useful to work toward a more reproducible reference testing procedure.

Agreement already existed regarding several elements of the procedure. For example, to facilitate additional analysis of various test conditions, it was agreed that the reference method should be a broth dilution procedure. Because of examples of drug antagonism by some complex media for certain antifungal agents, the subcommittee restricted its interest to fully defined synthetic media only. Drug stock solution preparation and dilution procedures previously developed for antibacterial testing procedures were adopted with minor modifications. Despite agreement in some areas, for other factors, additional data needed to be resolved, including:

- Inoculum preparation
- Inoculum size
- Choice among several synthetic media
- Incubation temperature
- Incubation duration
- End-point definition

These factors were the focus of a series of collaborative studies.¹⁻⁴ As a result, the subcommittee reached agreement on all factors, which led to the publication of M27-P in 1992. In the next four years, reference minimal inhibitory concentration (MIC) ranges were established for two QC strains for the available antifungal agents,^{5,6} and broth microdilution procedures paralleling the broth macrodilution reference procedure became available.^{4,7-9} This information was included in a revised standard in 1995 (M27-T). In revising the standard, the subcommittee focused its attention on developing relevant breakpoints for available antifungal agents,¹⁰ included in M27-A in 1997. Since then, the subcommittee has developed 24- and 48-hour reference MIC ranges for microdilution testing of both established and newly introduced antifungal agents.¹¹ The study results are included in this standard and CLSI document M60.¹²

Overview of Changes

This standard replaces the previous edition of the approved standard, M27-A3, published in 2008. Several changes were made in this edition, including:

- **General:**
 - Revised document format and organization to reflect the CLSI quality system essential and path of workflow document templates and the updated CLSI style
 - Updated references to the previous informational supplements (M27-S4 and M44-S3) to reflect CLSI document M60,¹² the new supplement for broth dilution and disk diffusion yeast susceptibility testing
 - Added references to epidemiological cutoff values and CLSI documents M57¹³ and M59¹⁴

- **Subchapter 1.4.2, Definitions:**
 - Revised the breakpoint and interpretive category definitions for consistency with other CLSI antimicrobial susceptibility testing documents
 - Added definitions for “wild-type” and “non-wild-type”
 - Deleted all uses of the phrase “interpretive criteria”
- **Chapter 3, Antifungal Susceptibility Testing Process:**
 - Added an antifungal susceptibility testing process flow chart
 - Replaced procedural text with step-action tables
 - Added an explanation for deleting breakpoints for itraconazole and flucytosine
 - Changed recommended reading time for broth microdilution to 24 hours only for clinical isolates and QC strains (24 and/or 48 hours was accepted for some antifungal agents in M27-A3)
 - Deleted results interpretation information for ketoconazole

NOTE: The content of this standard is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

Key Words

Antifungal agent, broth macrodilution, broth microdilution, susceptibility testing, yeasts

Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

Chapter 1: Introduction

This chapter includes:

- Standard's scope and applicable exclusions
- Background information pertinent to the standard's content
- Standard precautions information
- "Note on Terminology" that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the standard
- Abbreviations and acronyms used in the standard

1.1 Scope

This standard describes a reference method for testing susceptibility to antifungal agents of yeasts that cause infections, including *Candida* spp. and *Cryptococcus* spp. The intended users are laboratory personnel who perform antifungal susceptibility testing on yeasts. The focus is on developing relevant breakpoints for available antifungal agents¹⁰ and reference minimal inhibitory concentration (MIC) ranges for broth dilution testing of both established and newly introduced antifungal agents.¹¹ For MIC breakpoints, interpretive categories, and MIC ranges for QC isolates, refer to CLSI document M60.¹²

This method has not been extensively validated for the yeast forms of dimorphic fungi, such as *Blastomyces dermatitidis* or *Histoplasma capsulatum*. Also, testing filamentous fungi (moulds) introduces several additional standardization problems not covered by this procedure and is not included. For an antifungal broth dilution susceptibility testing reference method for filamentous fungi, refer to CLSI document M38.¹⁵

Commercially available susceptibility test systems are out of scope for this standard. It is recommended that users of these systems refer to the manufacturer's instructions as outlined in the package insert.

1.2 Background

This standard provides a reference method developed through a consensus process to facilitate agreement among laboratories in measuring yeast susceptibility to antifungal agents. An important use of a reference method is to provide a standard basis from which other methods can be developed, which also results in interlaboratory agreement within specified ranges. For example, broth microdilution methods using an indicator dye to facilitate breakpoint determinations have been configured to produce results paralleling those obtained by the broth microdilution reference method. To the extent that any method produces results concordant with this reference method, it would be considered to conform with this standard.

1.3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory.¹⁶ For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.¹⁷

1.4 Terminology

1.4.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization whenever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in different countries and regions and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. CLSI recognizes its important role in these efforts, and its consensus process focuses on harmonization of terms to facilitate the global application of standards and guidelines.

NOTE: Current fungal taxonomy is being revised. Many genera have both a teleomorph (sexual state) and an anamorph (asexual state) name. In this standard, the traditional *Candida* spp. and *Cryptococcus* spp. names are used to provide continuity to both past procedures and associated documents such as CLSI document M60.¹²

1.4.2 Definitions

antibiogram – overall profile of antimicrobial susceptibility testing results of a microbial species to a battery of antimicrobial agents.

breakpoint – minimal inhibitory concentration (MIC) or zone diameter value used to categorize an organism as susceptible, susceptible-dose dependent, intermediate, or resistant; **NOTE 1:** MIC or zone diameter values generated by a susceptibility test can be interpreted based upon established breakpoints; **NOTE 2:** See **interpretive category**.

epidemiological cutoff value (ECV) – the minimal inhibitory concentration (MIC) or zone diameter value that separates microbial populations into those with and without acquired and/or mutational resistance based on their phenotypes (wild-type or non-wild-type). The ECV defines the upper limit of susceptibility for the wild-type population of isolates.

EXAMPLE:

Interpretive Category	ECVs	
	MIC, µg/mL	Zone Diameter, mm
Wild-type	≤4	≥20
Non-wild-type	≥8	≤19